Dr. Christian Hinrichs is a medical oncologist and tumor immunologist who has pioneered curative cell therapies for HPV-associated cancers. He initially trained in general surgery at the University of Missouri–Kansas City and in surgical oncology at Roswell Park before pursuing cancer research through a post-doctoral fellowship in tumor immunology at the NCI with Nicholas P. Restifo, M.D., and Steven A. Rosenberg, M.D., Ph.D. He subsequently completed his internal medicine residency at George Washington University and medical oncology fellowship at the National Cancer Institute. At the NCI, Dr. Hinrichs was selected for the Clinical Investigator Development Program, honored as a NIH Lasker Clinical Research Scholar, and awarded tenure. His team has shown that tumor-infiltrating lymphocyte therapy can induce durable complete regression (apparently curative responses) in HPV-associated cancers and has mapped the tumor antigen landscape underlying these responses. They have also demonstrated the clinical activity of E7-specific TCR-engineered T cells in metastatic cancers, including immunotherapy-refractory disease, and identified tumor-intrinsic resistance mechanisms that inform next-generation treatments. His team has built a portfolio of therapeutic TCRs for a range of common cancers and advanced engineering strategies, including membrane-anchored cytokines, to enhance cell therapy potency with limited systemic exposure. In 2021, Dr. Hinrichs founded the cell therapy program at Rutgers Cancer Institute, where he serves as co-director of the Cancer Immunology and Metabolism Center of Excellence and chief of the cancer immunotherapy section.